350 руб
Журнал «Технологии живых систем» №8 за 2012 г.
Статья в номере:
Анализ прогностических факторов возникновения осложнений внутритканевой лучевой терапии в комплексном лечении рака предстательной железы
Ключевые слова: рак предстательной железы ранние лучевые повреждения поздние лучевые повреждения брахитерапия
Авторы:
А.Ю. Павлов, А.Д. Цыбульский, П.В. Даценко, И.А. Альбицкий, А.В. Семин, Р.И. Аби-Хайдар, А.В. Шестаков
Аннотация:
Приведены прогностические признаки развития осложнений после внутритканевой лучевой терапии рака предстательной железы. Причины развития осложнений были разделены по группам  анатомо-функциональ-ные, механические и дозиметрические.
Страницы: 52-56
Список источников
  1. Sylvester J., Blasko J.C., Grimm P., Ragde H. Interstitial implantation techniques in prostate cancer // J. Surg. Oncology. 1997. V. 66. P. 65-75.
  2. Potters L., Klein E.A., Kattan M.W., et al. Monotherapy for stage T1-T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent seed implantation // Radiotherapy Oncology. 2004. V. 71. P. 29-33.
  3. Ash D., Bottomley D., Al-Qaisieh B., Carey B., Gould K., Henry A. A prospective analysis of long-term quality of life after permanent I-125 brachythrapy for localised prostate cancer // Radiotherapy Oncology. 2007. V. 84. P. 135.
  4. Bottomley D., Ash D., Al-Qaisieh B., et al. Side effects of permanent I125 prostate seed implants in 667 patients treated in Leeds // Radiotherapy Oncology 2007. V. 82 P. 46-49.
  5. Brandeis J.M., Litwin M.S., Burnison C.M., Reiter R.E. Quality of life outcomes after brachythrapy for early stage prostate cancer // J. Urology. 2000. V. 163. P. 851-857.
  6. Cesaretti J.A., Kao J., Stone N.N., Stock R. Effect of low doserate prostate brachytherapy on the sexual health of men with optimal sexual function before treatment: analysis at 7 years of follow-up // BJU Int. 2007. V. 100. P. 362-367.
  7. Henderson A., Ismail A.K.A., Cunningham M.,
    et al.     Toxicity and early biochemical outcomes from 125iodine prostate brachythrapy in the UK. A prospective study // Clinical Oncology. 2004. V. 16.  P. 95-104.
  8. Merrick G.S., Wallner K.E., Butler W.M. Minimizing prostate brachytherapy-related morbidity // Urology 2003. V. 62. P. 786-792.
  9. Merrick G.S., Butler W.M., Wallner K.E., et al. Long-term rectal function after permanent prostate brachythrapy // Cancer journal. 2007. V. 13. P. 95-104.
  10. Miller D.C., Sanda M.G., Dunn R.L., et al. Long term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachythrapy // Journal of Clinical Oncology. 2005. V. 23. P. 2772-27780.
  11. Van Gellekom M.P.R., Moerland M.A., van Vul-
    pen M., Wijrdeman H.K., Battermann J.J.     Quality of life of patients after permanent prostate brachytherapy in relation to dosimetry // Journal of Radiation Oncology and Biological Physics. 2005. V. 63. P. 772-780.
  12. Allen Z.A., Merrick G.S., Butler W.M., et al. Detailed urethral dosimetry in the evaluation of prostate brachytherapyrelated urinary morbidity // Journal of Radiation Oncology and Biological Physics. 2005. V. 62. P. 981-987.
  13. Williams S.G., Millar J.L., Duchesne G.M.,
    Dally M.J., Royce P.L., Snow R.M.     Factors predicting for urinary morbidity following 125iodine transperineal prostate brachytherapy // Radiotherapy oncology. 2004. V. 73. P. 33-38.
  14. Gelblum D., Potters L., Ashley R., Waldbaum R., Wang X.H., Leibel S. Urinary morbidity following ultrasound-guided transperineal prostate seed implantation // Radiation Oncology and Biological Physics. 1999. V. 45. P. 59-67.
  15. Barry M.J., Fowler F.J., O-Leary M.P. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association // Journal of Urology. 1992. V. 148. P. 1549-1557.
  16. Steggerda M.J., van der Poel H.G., Moonen L.M.F. An analysis of the relation between physical characteristics of prostate I-125 seed implants and lower urinary tract symptoms: bladder hotspot dose and prostate size are significant predictors // Radiotherapy oncology. 2008 V. 88. P. 108-114.